• News
  • Medical

DexCom climbs on strong 3Q sales, outlook

Related Special Reports

Shares of DexCom jumped Thursday after the medical device maker's third-quarter sales surpassed Wall Street forecasts.

San Diego-based DexCom (Nasdaq: DXCM) said Wednesday that it lost $6 million, or 8 cents per share, in the latest quarter. A year ago it lost $17.3 million, or 25 cents per share. Revenue climbed to $42.9 million from $23.1 million as its product revenue doubled to $42.5 million.

Analysts expected the company to take a loss of 13 cents per share on $35.8 million in revenue, according to FactSet.

DexCom makes wireless systems that diabetes patients can use to monitor their blood sugar. The Food and Drug Administration approved its G4 Platinum system in 2012. The company says G4 Platinum is more accurate than its older system Seven Plus, especially when patients are hypoglycemic. It has a smaller sensor and longer transmission range. It also it sends an alert if the patient's blood sugar gets to a specific low level and offers customizable alerts.

The said it expects to exceed its forecast of $140 million in revenue this year, and it ultimately expects revenue to grow at an annual rate of about 40 percent.

Analysts expect DexCom to report $140.8 million in revenue in 2013.

Benchmark Co. analyst Jan Wald said new users, sensor sales, and sensor use are increasing. He said the marketing is accepting G4 Platinum, and DexCom will now be able to focus on expanding its use and enhancing the features of the device.

Wald rates the shares “buy” with a price target of $40.

Shares of DexCom gained $5.79, or 21.3 percent, to $33.03 in afternoon trading. The stock has more than doubled in value in 2013 and is trading at all-time highs. It went as high as $33.73 on Thursday.

User Response
0 UserComments